维普期刊资源整合服务平台（V6.5）

76篇 您的检索式：作者名="Politi KA"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
2	Acquired resistance of lung adeno- carcinomas to gefitinib or erlotinib isassociated witha second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLoS Meal2005，2，3：	1
3	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA		0，，03：	1
4	Update on epidermal growth factor receptor mutations in non-small cell lung cancer 显示文摘	Riely GJ Politi KA Miller VA	2006	ClinCancerRes2006，12，24：	1
5	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
6	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLOS MEDICINE2005，2，3：	1
7	Acquired resistance of lung ade- nocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR klnase domain 显示文摘	Pao W VA Miller KA Politi	2005	Plos Med2005，2，3：	1
8	Acquired resistance of lungadenocarcinomas to gefitinib or erlotinib is associated with asecond mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Medi2005，2，3：	1
9	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associat- ed with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
10	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
11	Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA		0，，03：	1
12	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinih is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
13	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
14	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	PAO W MILLER VA POLITI KA	2005	Plos Med2005，2，3：	1
15	Acquired resistance oflung adenocarcinomas to gefitinib or erlotinib is associatedwith a second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
16	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain 显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
17	Acquired resist- ance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR ki- nase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
18	Acquired resistance of lung adenocareinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
19	Acquired resistance of lung adeno- carcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，3：	1
20	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘	Pao W Miller VA Politi KA	2005	PLoS Med2005，2，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示